Rocket Pharmaceuticals (Rocket Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Jun. 05, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-06-05), Rocket Pharmaceuticals's share price is $22.84. Rocket Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.25. Hence, Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

RCKT's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.785
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Rocket Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.61. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.25.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -19.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -15.50% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 6.80% per year.

During the past 12 years, Rocket Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 38.20% per year. The lowest was -25.60% per year. And the median was -10.60% per year.

Rocket Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Rocket Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Rocket Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	22.84	/	-2.246
	=

Rocket Pharmaceuticals's Share Price of today is $22.84.
Rocket Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.25.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Rocket Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

9IP1:Germany

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Executives

John Militello	officer: See Remarks	C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker	director	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah	director, officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel	officer: Chief Operating Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White	officer: Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson	officer: General Counsel	C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada	officer: Chief Financial Officer	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork	director	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam	officer: SVP - Finance & PFO	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell	director, officer: See Remarks	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi	director	412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder	officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016